Trial Profile
Open-label Study of Bevacizumab Maintenance Therapy (AVASTIN) With or Without Pemetrexed After First-line Chemotherapy With Bevacizumab-cisplatin-pemetrexed in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms AVAPERL; AVAPERL-1
- Sponsors Roche
- 08 Jul 2013 Results published in the Journal of Clinical Oncology.
- 04 Jun 2013 Updated overall survival analysis presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.